The GSK vaccine Arexvy has been accepted for regulatory review by the European Medicines Agency (EMA) for use in adults aged 50-59 who are at increased risk for respiratory syncytial virus (RSV). This vaccine is being considered for approval to protect this at-risk population from RSV. Additionally, the website uses cookies for analytics, advertising, and site improvement, and users agree to their use by continuing to use the site. Users can find more information about the use of cookies in the Cookie Policy and Cookie Settings.
Source link
GSK vaccine Arexvy accepted for regulatory review by EMA for adults aged 50-59 at increased risk for RSV
